In fiscal year 2025, 에임드바이오 (0009k0) reported revenue of 47.3 billion KRW.
Income Statement
| Year | Revenue | Op Profit | Net Income | Source |
|---|---|---|---|---|
| 2025 | 47.3 billion KRW | 20.8 billion KRW | 5.0 billion KRW | [source] |
| 2024 | 11.8 billion KRW | -408 million KRW | -3.3 billion KRW | — |
| 2023 | 171 million KRW | -6.4 billion KRW | -9.0 billion KRW | — |
Balance Sheet
| Year | Total Assets | Total Liabilities | Total Equity | Source |
|---|---|---|---|---|
| 2025 | 199.0 billion KRW | 6.4 billion KRW | 192.6 billion KRW | [source] |
| 2024 | — | — | — | — |
| 2023 | — | — | — | — |
Cash Flow
| Year | Operating | Investing | Financing | Source |
|---|---|---|---|---|
| 2025 | 17.9 billion KRW | -33.9 billion KRW | 118.5 billion KRW | [source] |
| 2024 | — | — | — | — |
| 2023 | — | — | — | — |
Years without a source link are outside the DART financial API collection period.
Balance sheet figures for the relevant year were not collected.
Cash flow figures for the relevant year were not collected.